Treatment of cognitive impairment in multiple sclerosis.
Cognitive impairment in multiple sclerosis is an increasingly recognized entity. This article reviews the cognitive impairment of multiple sclerosis, its prevalence, its relationship to different types of multiple sclerosis, and its contribution to long-term functional prognosis. The discussion also focuses on the key elements of cognitive dysfunction in multiple sclerosis which distinguish it from other forms of cognitive impairment. Therapeutic interventions potentially effective for the cognitive impairment of multiple sclerosis are reviewed including the effects of disease modifying therapies and the use of physical and cognitive interventions.
Pierson
Susan H
SH
Drake Center, Department of Neurology, University of Cincinnati, 151 West Galbraith Road, Cincinnati, OH 45216, USA. SPierson@CapeCodHealth.org
Griffith
Nathan
N
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology* / Q000534:rehabilitation / Q000628:therapy*; D015928:Cognitive Behavioral Therapy / Q000379:methods*; D003863:Depression / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D005221:Fatigue / Q000150:complications / Q000175:diagnosis / Q000628:therapy; D000068717:Glatiramer Acetate; D006801:Humans; D000068556:Interferon beta-1a; D016899:Interferon-beta / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000145:classification / Q000150:complications* / Q000523:psychology* / Q000628:therapy; D009483:Neuropsychological Tests; D010455:Peptides / Q000627:therapeutic use; D011788:Quality of Life / Q000523:psychology*; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D010455:Peptides; D000068717:Glatiramer Acetate; D016899:Interferon-beta; D000068556:Interferon beta-1a